Oxytocin is a nine-amino-acid peptide hormone that binds to the oxytocin receptor, which is a member of the G protein-coupled receptor family, to regulate a range of physiologic processes, including eating behaviour and metabolism. Produced in the supraoptic nucleus and paraventricular nucleus (PVN) of the hypothalamus, oxytocin is released to brain regions involved in energy metabolism via dendritic diffusion (for example, the ventromedial nucleus of the hypothalamus (VMH) 1,2 ) as well as axonal connections of parvocellular oxytocin neurons to other regions, including the arcuate nucleus (ARC) 3 , ventral tegmental area (VTA) 4 , nucleus accumbens 5 , nucleus tractus solitarius (NTS) 6,7 and spinal cord 7, 8 . There are also axonal connections of magnocellular oxytocin neurons to the posterior pituitary gland, which secretes oxytocin to the peripheral circulation. In addition, oxytocin is produced and released in local tissues, such as the gastrointestinal tract 9 , where oxytocin has autocrine and paracrine effects via oxytocin receptors 10, 11 . Although endogenous oxytocin does not readily cross the blood-brain barrier, behavioural studies indicate that circulating oxytocin might directly enter the hindbrain or act on the vagus nerve [12] [13] [14] [15] , and a study in nonhuman primates indicates that oxytocin at supraphysiologic concentrations administered intravenously or intranasally enters the cerebrospinal fluid (CSF) 16 .
, where oxytocin has autocrine and paracrine effects via oxytocin receptors 10, 11 . Although endogenous oxytocin does not readily cross the blood-brain barrier, behavioural studies indicate that circulating oxytocin might directly enter the hindbrain or act on the vagus nerve [12] [13] [14] [15] , and a study in nonhuman primates indicates that oxytocin at supraphysiologic concentrations administered intravenously or intranasally enters the cerebrospinal fluid (CSF) 16 .
Furthermore, exogenous oxytocin administration might promote endogenous oxytocin secretion either directly through PVN oxytocin autoreceptors or indirectly through peripheral oxytocin receptors 17, 18 . The oxytocin receptor is widely distributed in the central nervous system (for example, the hypothalamus, basal ganglia, VTA, nucleus accumbens, frontal cortex, insula, NTS and spinal cord) and peripheral regions that are key for the control of food intake and metabolism (for example, the vagus nerve, anterior pituitary gland, adipocytes, gastrointestinal tract and pancreas) 8, 10, 11, [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] . Animal studies indicate that oxytocin is a potent regulator of caloric intake and metabolism 8, 14 . Oxytocin or oxytocin receptor knockout mice gain weight and develop late-onset obesity [32] [33] [34] and impaired glucose homeostasis 34 . In addition, mice with haplo insufficiency of single-minded homologue 1 (encoded by Sim1; mutations in SIM1 are associated with hyperphagic obesity in humans) have low levels of oxytocin mRNA in the hypothalamus, and oxytocin administration reverses their excessive food intake and weight gain 35 . Exogenous oxytocin administration in mice, rats and monkeys, whether given centrally or peripherally, leads to sustained weight suppression by reducing food intake, increasing or maintaining energy expenditure, and promoting lipolysis 8, 14, 18, [36] [37] [38] . Independently of effects on weight, oxytocin administration can improve glucose homeostasis in diet-induced obese or diabetic rodents 18, 36 . These findings in animals indicate that pathways involving oxytocin might provide novel therapeutic targets for obesity and metabolic disorders. Clinical investigations are beginning to translate these important findings to humans.
Measurement of oxytocin in samples
In interpreting human data, it is important to recognize that measurement of oxytocin levels in blood samples is controversial and rigorous validations of assays have not been performed 39, 40 . Older radioimmunoassays yielded results similar to those of bioassays and typically reported oxytocin levels after extraction of <10 pg/ml in healthy young men and nonpregnant or lactating women, with levels up to 24 pg/ml during lactation and 114 pg/ml during labour 39 . Unfortunately, using newer commercially available radioimmunoassays can result in falsely inflated oxytocin levels because of interference from other substances (that is, the assay might falsely identify substances as oxytocin) 41 . In the past decade, most publications reporting oxytocin in serum or plasma samples have used commercially available enzyme-linked immunosorbent assays (ELISAs), which yield levels that are up to two orders of magnitude higher than traditional radio immunoassays when extraction is not performed 39 . Extraction before the ELISA filters out some, but not all, of the interfering substances and yields overall levels of similar magnitude to the traditional radio immunoassays 41 . The ELISA might detect oxytocin fragments or degradation products, and the biological activity of these molecules is unknown 41 . In a paper published in 2016, it was posited that extraction might result in falsely low oxytocin levels due to elimination of protein-bound oxytocin 42 . In sum, studies that use immunoassays to quantify oxytocin levels are measuring oxytocin immunoreactive products, not absolute values of oxytocin, and levels cannot be compared between studies. However, these assays might be useful for the comparison of relative levels of peripheral oxytocin between groups and investigating the relationship between oxytocin levels and relevant clinical end points.
Newer techniques free oxytocin from protein binding by reduction-alkylation reactions and then quantify it by liquid chromatography-mass spectrometry (LC-MS) 42 . After interfering substances are removed by solid phase extraction, the samples undergo highperformance liquid chromatography separation and measurement by mass spectrometry, which is highly selective and sensitive. The addition of a stable isotope of oxytocin (5× deuterated oxytocin) as the first step during LC-MS analysis enables accurate corrections for any loss of analytes or gain in signal strength due to concentration. With this methodology, oxytocin levels in the ng/ml range (which is ≥1,000 times the levels reported with traditional techniques) have been reported 42 . These data suggest that much of the oxytocin that is present under physio logical conditions is protein bound and not measured by traditional approaches. The biological relevance of protein-bound versus free oxytocin is an important question to be investigated.
One must consider several other caveats when interpreting data on oxytocin levels. First, central and peripheral oxytocin secretion might be coordinated or independent of one another, and therefore, peripheral levels might not reflect central functioning [43] [44] [45] [46] . Second, CSF levels of oxytocin might not mirror activity in specific brain circuits. Third, blood levels of oxytocin might not reflect local autocrine and/or paracrine oxytocin activity. Finally, the measurement of oxytocin in other biological samples (for example, urine and saliva) is not well validated, and the biological importance of these data is not yet clear 39 .
Oxytocin dose
Oxytocin is typically given intravenously at doses of 1-30 mIU per min during labour and 10 IU postpartum to prevent haemorrhage (1 mg of oxytocin is equivalent to 600 IU (WHO International Standard); therefore, a dose of 1 mIU per min is approximately 1.7 ng per min). Metabolic studies in humans have often used doses that are higher than the 1 mIU per min required for inducing contractions in pregnancy or the estimated 14 IU of oxytocin contained in the human posterior pituitary gland 47 . Doses used in these studies are therefore supraphysiologic, even when differences in routes of administration are taken into account 48 . Evidence indicates that oxytocin at a supraphysiologic dose (80 IU) delivered either intranasally or intravenously crosses the blood-brain barrier 16 and therefore might have direct central effects in addition to peripheral effects. Some of the effects seen at supraphysiologic doses might be due to oxytocin acting at vasopressin receptors 49 . Studies are needed to clarify the relative contributions of these receptors in mediating the effects of exogenous oxytocin.
Eating behaviour
Experiments in rodents, nonhuman primates and humans consistently show that oxytocin reduces caloric consumption 14, 18, 35, [50] [51] [52] . These effects are almost immediate, and in animal models they are sustained with repeated dosing 14, 18, 37, 38, 50, 51 . With the exception of one study demonstrating that oxytocin reduces food intake
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• Animal studies indicate that oxytocin is a potent regulator of caloric intake and metabolism; clinical investigations are beginning to translate these findings to humans • A single dose of intranasal oxytocin reduces caloric intake in men, particularly of more palatable foods, and these effects could be increased in men with obesity • Intranasal oxytocin acutely increases the use of fat as a fuel for the body, but effects of oxytocin in promoting energy expenditure have not been demonstrated in humans • An 8-week pilot study of intranasal oxytocin in a small group of men and women with overweight or obesity led to substantial weight loss • Independently of effects on body weight, oxytocin might improve glucose homeostasis, but the data are conflicting • Pathways that involve oxytocin offer novel therapeutic targets for obesity and metabolic disease and weight gain in female Sim1 haploinsufficient mice 35 , most studies have included only males, leaving the question of whether oxytocin also reduces food intake in females unclear. Interestingly, obese rodents seem to be more sensitive to oxytocin treatment than their lean counterparts 38 . Preclinical studies have demonstrated a preferential effect of oxytocin in reducing carbohydrate consumption 14, [53] [54] [55] [56] . Although some rodent studies have not found that oxytocin affects intake of lipid emulsions 54, 55 , others have demonstrated that oxytocin suppresses consumption of high-fat diets 17, 18, 37, 38 . Preclinical studies implicate central (homeostatic, for example, VMH and ARC 1, 3 , and hedonic, for example, VTA and nucleus accumbens) 4, 5 , autonomic (NTS and dorsal motor nucleus of the vagus) 6, 7 and peripheral (gastrointestinal system and vagus nerve) 37, [57] [58] [59] [60] signalling pathways in the modulation of food intake. Furthermore, oxytocin might affect appetite indirectly by altering levels of other appetite-regulating hormones (for example, by increasing levels of the anorexigenic hormones cholecystokinin (CCK) and glucagon-like peptide 1 (GLP1)) 57, 61, 62 . Evidence increasingly suggests that in humans, oxytocin is involved in normal and aberrant eating behaviours. In anorexia nervosa, an eating disorder characterized by severe chronic food restriction despite self-starvation and markedly low weight, low CSF levels of oxytocin were found in five women with low-weight restrictive 63 (but not low-weight 63 or weight-restored binge-purge 64 ) anorexia nervosa compared with controls. In addition, peripheral levels of oxytocin in response to stimulation were suppressed in seven lowweight women with anorexia nervosa; levels normalized with weight restoration 65 . Low basal serum levels of oxytocin have also been reported in acute (low-weight) and partially recovered (normal-weight) women with anorexia nervosa [66] [67] [68] . Furthermore, postprandial oxytocin levels have been linked to the severity of eating disorder psychopathology and fMRI-detected hypoactivation of food motivation neural circuitry in low-weight and weight-restored women with anorexia nervosa, which suggests that oxytocin might have a role in the aetiology of anorexia nervosa 69 
. By contrast, several studies have not demonstrated differences in CSF levels of oxytocin between women with active 63 or recovered 64 bulimia nervosa and healthy individuals.
Furthermore, no differences were found in basal or stimulated peripheral levels of oxytocin between women with bulimia nervosa and controls 65, 68 . In the past 5 years, studies in women have identified associations between genetic variation in the oxytocin receptor and eating disorder diagnosis (bulimia nervosa) 70 , eating disorder thoughts and behaviours (in those with anorexia nervosa and in a community sample of women) [71] [72] [73] , food preoccu pation (in anorexia nervosa) 71 and reported nutrient intake (in a community sample of women) 72 . A single-dose randomized placebo-controlled crossover study of 40 IU intranasal administration of oxytocin in women showed that oxytocin reduced self-reported food intake in the subsequent 24 h in women with bulimia nervosa but not in women with anorexia nervosa or healthy controls 74 ; however, a test meal was not used. In a study of intranasal administration of oxytocin (12-24 IU twice a day) in boys and girls with PraderWilli syndrome (a genetic syndrome characterized by severe early-onset obesity and hyperphagia), 4 weeks of oxytocin treatment reduced the incidence of abnormal food-related behaviours (for instance, preoccupation with food) in a subset of younger children (those aged 6-10 years) but not in children aged 11-14 years 75 .
Oxytocin did not affect food intake at a test meal in these children; however, the ability to detect a difference was hindered by the fairly small size of the meal, which was finished in its entirety by nearly all participants, who had hyperphagia 75 . To date, three human studies -all exclusively in men -that investigated the effects of intranasal administration of oxytocin on food intake in individuals without eating disorders have been published 51, 52, 76 . In a randomized, placebo-controlled crossover study of a single intranasal dose of 24 IU of oxytocin in 25 healthy men without diabetes mellitus (13 normal-weight men and 12 with overweight or obesity), oxytocin reduced caloric intake at a breakfast test meal by 122 kcal with a preferential effect on fat consumption; intake of fat was significantly reduced, while intake of carbohydrates and protein was not significantly reduced 51 
. Although initial work using the same intranasal dose of oxytocin in normal-weight men did not show suppression of caloric intake at a breakfast buffet 52 , a follow-up study demonstrated a reduction of 147 kcal in men with obesity 76 , which is consistent with the animal data that suggest that obesity is a particularly oxytocin-sensitive state 38 . The authors found that oxytocin reduced consumption of a postprandial snack, particularly chocolate cookies, to a similar extent in men who were normal weight and those who had obesity 76 . Each of the three human studies 51, 52, 76 used visual analogue scales to assess changes in appetite and found no evidence that oxytocin affected participants' self-reports of fasting or postprandial appetite, which demonstrates that oxytocin might alter eating behaviour without the awareness of the individual. This finding is consistent with reports from smaller studies showing no effects of intravenous administration of oxytocin on subjective satiety in healthy individuals 77 or in patients with diabetic gastroparesis or functional dyspepsia 78 but is in contrast to one study that reported reduced satiety in healthy individuals 79 . Furthermore, several small studies using intravenous infusions of oxytocin (20-80 mIU per min) in men and women who were healthy 79 or had functional dyspepsia 78 found that oxytocin had no effect on the volume of liquid meal intake required to induce satiety. These data highlight the importance of obtaining objective measures, such as food intake at a test meal and/or brain imaging, in this line of research.
The relationship between postprandial serum levels of oxytocin and fMRI-detected hypoactivation of the hypothalamus (a brain region critical to homeostatic regulation of food consumption), as well as hypo activation of areas responsible for reward-driven eating, such as the orbitofrontal cortex, in response to visual food stimuli in women with anorexia nervosa 69 supports preclinical evidence of oxytocin's role in both homeostatic and hedonic food motivation 8 . In addition, the preferential effects of intranasal administration of oxytocin in reducing consumption of more palatable foods, such as fats and carbohydrates, by men 51, 52, 76 is consistent with the concept that oxytocin might inhibit food intake in part by modulating reward-related food motivation and/or impulse control neurocircuitry. This concept is in line with a study published in 2016 showing that a single intranasal dose of 24 IU of oxytocin increased activation of brain circuitry involved in cognitive control (detected by fMRI) and, at the trend level, reduced food craving when women were asked to cognitively control the urge to eat while viewing images of palatable foods 80 . This finding is also consistent with animal studies demonstrating that sucrose intake was inhibited following administration of oxytocin to the VTA 56 or nucleus accumbens 81 , which are regions of the brain involved in reward that receive oxytocin projections from the PVN 4 and express oxytocin receptors [23] [24] [25] . Further research examining the specific effects of oxytocin on caloric intake and its underlying mechanisms in humans will be important (FIG. 1) .
Peripheral sites of oxytocin action have also been implicated as potential modulators of appetitive behaviours. Studies in rats suggest that oxytocin induces satiety in part by slowing gastric emptying [57] [58] [59] [60] . The data in humans, however, are inconsistent; one study in patients with diabetic gastroparesis reported a prolongation of gastric emptying time (40-80 mIU per min) 78 , whereas studies in healthy individuals showed no effect (40 mIU per min) 77 or even an acceleration of gastric emptying (0.33 IU per min) 82 following intravenous administration of oxytocin. Although a study in healthy men and women found that the oxytocin antagonist atosiban increased gastric emptying time 77 , the authors speculate that these effects could have been due to actions at the vasopressin receptor. These conflicting results might reflect differences in the populations studied and/or small sample sizes. Two studies have examined the effects of oxytocin on the colon in humans. In women, intravenous administration of oxytocin (20 mIU per min or 40 mIU per min) increased colonic motility in response to a lipid infusion through a feeding tube 83 . In a study of 26 patients with irritable bowel syndrome and constipation, intra venous administration of oxytocin at doses of 20-50 mIU per min reduced their perception of colonic distention 84 . The clinical importance of these findings is unclear, and further studies are needed to determine dose-specific and population-specific effects of oxytocin on gastro enterological function and appetitive behaviours.
Several studies in humans have examined the effects of oxytocin on other appetite-regulating hormones. While intravenous administration of oxytocin reduces the typical lipopolysaccharide-induced increase in levels of ghrelin (which is orexigenic) 85 , 24 IU intranasal administration of oxytocin did not result in statistically significant changes in fasting or postprandial levels of ghrelin 51, 52 . Oxytocin increased CCK levels, but this change was not related to differences in caloric consumption between the oxytocin and placebo conditions 51 . Oxytocin had no statistically significant effects on the levels of the anorexigenic hormones leptin, GLP1 or peptide YY 51, 52 . Reduced levels of cortisol, which have been previously demonstrated in animal and human studies, were associated with reduced consumption of chocolate cookies in normal-weight (but not obese) men receiving oxytocin 52, 76 . In future studies, it will be important to examine the effects of oxytocin on other appetite-regulating hormones and whether some of the effects of oxytocin on caloric intake could be mediated by other hormones.
Lipid metabolism and body fat
Preclinical studies indicate that oxytocin induces lipolysis 14, 18 and fat oxidation 18, 37, 86 , which in turn, independent of food intake, lead to reduced body fat and weight 18 . Notably, oxytocin reduces visceral and liver fat 37 , which are metabolically important fat depots that are associated with an increased risk of the metabolic syndrome and cardiovascular disease 87 . Endogenous peripheral levels of oxytocin are high in men and women with obesity 88, 89 , and oxytocin levels in different populations across the weight spectrum are correlated with weight, BMI and levels of body fat 66, [89] [90] [91] 
. A notable exception is a study showing low levels of oxytocin in adults with obesity compared with adults of normal weight; oxytocin levels were negatively associated with BMI 92 . However, these results might have been confounded by the fact that a large proportion of participants had type 2 diabetes mellitus, a condition associated with low oxytocin levels 92 . Published in 2016, results from the MINOS study of men aged 50-85 years demonstrated higher endogenous levels of oxytocin in men with the metabolic syndrome than in those without the metabolic syndrome. Furthermore, raised oxytocin levels were associated with increased odds of the metabolic syndrome after adjusting for confounders, including leptin levels 91 . High oxytocin levels were associated with increased central fat and waist circumference, which are surrogate markers for visceral fat 91 .
In the 1960s, an experiment in women showed that intravenous administration of oxytocin (10 mIU/kg) increased plasma levels of nonesterified free fatty acids and reduced plasma levels of triglycerides 93 , which is consistent with the lipolytic effect of oxytocin that has been demonstrated in animal models 14, 18 . Several human studies published in the past 5 years have used intranasal oxytocin as a physiologic probe to study the effects of oxytocin on lipid metabolism and body fat 36, 51 . A single dose of intranasal oxytocin (24 IU) in men resulted in a drop in respiratory quotient as assessed by indirect calorimetry 30 min after oxytocin administration, which is consistent with an increase in fat oxidation 51 
. In a small study of 8 weeks of sustained intranasal administration of oxytocin (24 IU before meals and at bedtime) in men and women who were overweight or had obesity, oxytocin led to weight loss with an improved lipid profile (lower levels of total cholesterol and LDL cholesterol) and reduced waist circumference 36 
. Imaging was not performed to assess for changes in total body fat or specific fat depots 36 . The study authors noted that oxytocin resulted in slightly improved liver function test results, which could reflect reduced hepatic steatosis 36 . Further studies are warranted to examine the effects of oxytocin on lipid metabolism and body fat depots.
Energy expenditure
A major barrier to maintenance of weight loss in humans is the physiologic reduction in energy expenditure that occurs with reduced food intake and weight 94 . Unlike existing pharmacological options, which primarily target food consumption or absorption, oxytocin not only reduces food intake but, in diet-induced obese rodent and nonhuman primate models, also promotes energy expenditure, which enables maintenance of weight reduction 14, 18, 38, 86 . How oxytocin increases energy expenditure is not yet clear; however, some preclinical evidence suggests that administration of oxytocin leads to preferential preservation of lean body mass, a key determinant of energy expenditure, despite weight loss 86 ; activation of brown fat [32] [33] [34] ; and/or the conversion of white adipose tissue to beige fat that is capable of thermogenesis 90, 95 . In young female athletes and nonathletes aged 14-21 years, fasting levels of oxytocin were positively associated with resting energy expenditure, providing the first evidence for such a link in humans 90 
. However, studies of a single intranasal dose of oxytocin (24 IU) in men with normal weight, overweight or obesity found no acute effect of oxytocin on resting or postprandial energy expenditure measured by indirect calorimetry 51, 52 . Chronic oxytocin exposure might be required to induce changes in energy expenditure, and effects on energy expenditure therefore might not have been captured in these singledose experiments. Whether sustained oxytocin will increase energy expenditure in humans as it does in animal models will be an important area of investigation.
Body weight
Oxytocin is emerging as a promising novel weight-loss therapy for obesity, as demonstrated by review articles published on this topic over the past several years 8, 96, 97 and current clinical research studies registered on ClinicalTrials.gov [98] [99] [100] . Experiments in rodents and nonhuman primates demonstrate that chronic peripheral or central administration of oxytocin results in sustained weight loss attributable to reduced food intake, maintenance of energy expenditure despite weight loss and increased lipolysis 14, 18, 37, 38, 86 . Human studies have shown that peripheral levels of oxytocin are low in patients with anorexia nervosa 66, 68 , high in those with obesity 88, 89 and positively associated with BMI and fat mass 66, 89 
. Furthermore, oxytocin levels drop with weight loss following gastric banding 88 . Together, these preclinical and clinical data suggest that oxytocin can act as a signal of energy availability: high oxytocin levels (for example, in obesity) appropriately signal the need to reduce caloric intake and increase energy expenditure.
Dysfunctional oxytocin signalling might contribute to weight gain in human genetic syndromes of severe obesity. In a genome-wide association study of white children in the UK, copy number variation in genes that encode proteins in the oxytocin receptor pathway was associated with severe early-onset obesity 101 . Furthermore, hypothalamic oxytocin deficiency has been implicated in the pathogenesis of Prader-Willi syndrome 102, 103 . In these patients, fairly low levels of oxytocin have been reported in the CSF 102 , and post-mortem studies have identified a reduced number of oxytocin-expressing neurons in the PVN of the hypothalamus 103 . In addition, polymorphisms of the oxytocin receptor (A-allele of rs53576) are associated with an increased risk of obesity in children of low socioeconomic status 104 . To date, only one study has examined whether oxytocin administration reduces body weight in humans who have overweight or obesity but are otherwise healthy. This randomized, placebo-controlled study of 24 IU of oxytocin delivered intranasally four times per day in men and women who were overweight or had obesity demonstrated that oxytocin led to substantial weight loss over 8 weeks 36
. This study was limited by a small sample size (nine participants were randomly assigned to receive oxytocin), and the groups were not well matched for age or baseline weight. However, the weight loss of approximately 9 kg (or 9%) with oxytocin was similar to the weight loss seen with the most effective FDA-approved medications for obesity 105, 106 . In contrast to the previously described study 36 , two randomized, placebo-controlled crossover studies of intranasal administration of oxytocin (12-40 IU twice daily) in children and adults with Prader-Willi syndrome did not result in statistically significant weight loss 75, 107 . Several potential explanations for the failure of oxytocin to reduce weight in these studies exist. First, the daily dose and frequency of oxytocin administration were lower than in the previous study. Second, Prader-Willi syndrome is associated with structural abnormalities of the PVN, including a reduced number of oxytocin neurons 103 ; it is therefore plausible that these patients might not be able to respond to exogenous oxytocin (for example, there may be a reduced number of hypothalamic oxytocin receptors and/or an inability to respond to oxytocin stimulation with endogenous oxytocin release) 107 . Third, children might have a different response to oxytocin than adults. Fourth, in one of the studies, weight was not a primary end point 75 .
Glucose homeostasis
Oxytocin receptors are present on α cells and β cells in pancreatic islets 29 . Furthermore, oxytocin administered at physiologic concentrations increases insulin release in the isolated rat pancreas 108 . Studies examining the effects of oxytocin on glucose homeostasis have yielded conflicting results and are very much dependent on the experimental model used. While some studies of central or peripheral administration of oxytocin in animal models (for example, in lean rats or obese diabetic ob/ob mice) have shown that oxytocin induces hyper glycaemia 26, 109 , others (for example, in lean or diet-induced obese mice, diet-induced obese rats, obese diabetic db/db mice, or streptozotocin-induced diabetic mice with impaired β-cell function) have clearly demonstrated the therapeutic potential of using oxytocin or oxytocin analogues to increase insulin secretion, insulin sensitivity and glucose tolerance independent of effects on weight or food intake 8, 17, 18, 36, 37, 95, 110, 111 . Human studies show inconsistent effects of oxytocin on glucose homeostasis, which might reflect differences in route of administration (for instance, intravenous versus intranasal and bolus versus continuous infusion), dose and/or populations studied. Acute effects of oxytocin on glucose homeostasis in humans were first demonstrated using intravenous administration of oxytocin more than 50 years ago. The study demonstrated that an intravenous bolus of oxytocin (10 mIU/kg) in postpartum women or women who were not pregnant or postpartum resulted in a dramatic lowering of blood levels of glucose over the 3-h experiment 93 . By contrast, another study of postpartum women found no effect of an intravenous dose of oxytocin (10 IU) on glucose or insulin levels 112 . This discrepancy might have been due to differences in dose, which was more than ten times higher in the second experiment than in the first experiment. In a small study of men, 6 IU (an initial dose of 2 IU plus an infusion of 4 IU over 1 h) but not 3 IU (an initial dose of 1 IU plus an infusion of 2 IU over 1 h) of intravenously infused oxytocin increased insulin levels in response to intravenous administration of glucose (0.33 g/kg) without affecting glucose levels or the glucagon, growth hormone or cortisol responses 113 . Another study reported that continuous intravenous infusion of oxytocin (0.2 IU per min over 60 min) resulted in hyper glycaemia, accompanied by increased release of glucagon, insulin and adrenaline and reduced release of cortisol in healthy young men aged 21-26 years 114 . Furthermore, in response to insulin-induced hypoglycaemia, oxytocin infused intravenously at this dose attenuated the drop in levels of glucose, increased levels of glucagon and adrenaline and reduced cortisol levels 114, 115 . By means of an euglycaemic euinsulinaemic clamp, it was also shown that the same dose of intravenous oxytocin increased hepatic glucose output in healthy young men aged 22-28 years 116 . Studies published in the past few years that used intranasal administration of oxytocin in men without diabetes mellitus have reported consistently beneficial effects on glucose homeostasis 51, 52, 76, 117 . In healthy men without diabetes mellitus who had normal weight, overweight or obesity, 24 IU of intranasally administered oxytocin (the same dose that is under investigation for weight loss in adults with obesity 36, 99 ) reduced fasting levels of insulin while maintaining normal levels of glucose, which resulted in improved insulin sensitivity 51
. In the fed state, 24 IU of oxytocin administered intranasally in separate groups of healthy normal-weight men and men with overweight or obesity reduced glucose levels without a change in insulin or C-peptide levels, independent of caloric intake 52, 76 
. In response to a 75-g oral glucose tolerance test, 24 IU of intra nasally administered oxytocin blunted the rise in levels of glucose and resulted in more rapid but attenuated insulin and C-peptide peaks in 29 healthy normal-weight men 117 . The authors found that oxytocin improved β-cell responsivity to the glucose challenge 117 
. However, a pilot study of intranasal administration of oxytocin (24 IU before meals and bedtime) for 8 weeks in a small group of men and women without diabetes mellitus who had overweight or obesity did not show statistically significant changes in fasting or postprandial levels of glucose or insulin despite weight loss 36 . Men and women with type 2 diabetes mellitus 92 and women with type 1 diabetes mellitus 118 have been shown to have lower levels of oxytocin than controls. Furthermore, in those with type 2 diabetes mellitus, low fasting levels of oxytocin were associated with higher levels of glucose and insulin, both after fasting and after an oral glucose tolerance test, as well as higher homeostatic model assessment of insulin resistance (HOMA-IR) and HbA 1c levels 92 
; these findings suggest that diabetes mellitus is a state of oxytocin deficiency. However, an experiment administering continuous intravenous infusion of oxytocin (0.2 IU per min) to patients with type 1 diabetes mellitus resulted in hyperglycaemia 115 , which is similar to findings with this dose and route of administration in healthy young men 114 . In summary, studies examining acute effects of intravenous oxytocin on glucose homeostasis in humans have shown mixed results, with low doses of oxytocin (10 mIU/kg, that is, ≤1 IU) reducing glucose levels and higher doses of oxytocin showing no effect (3-10 IU) or increasing (12 IU) glucose levels. While a number of studies of single-dose intranasal oxytocin (24 IU) in men without diabetes mellitus have resulted in improved glucose homeostasis, an 8-week study of short-term intranasal oxytocin (24 IU four times per day) did not yield improvement in glucose parameters despite causing weight loss. Further research examining dose-dependent effects of different routes of oxytocin administration, taking sex and physiologic context into account, is warranted. Studies in patients with prediabetes mellitus and diabetes mellitus will be particularly important.
Downregulation of the HPA axis
In addition to having direct beneficial metabolic actions, oxytocin might contribute additional complementary metabolic effects by downregulating activation of the hypothalamic-pituitary-adrenal (HPA) axis. The negative effects of cortisol on metabolism, including effects on lipid metabolism, body fat deposition and glucose homeostasis, are well established 119 . Oxytocin receptors are located in the anterior pituitary and adrenal glands 30, 120 , and intravenous or intranasal administration of oxytocin in humans reduces levels of adreno corticotropic hormone and cortisol under basal and stress conditions [121] [122] [123] [124] [125] 
. Intravenous administration of oxytocin completely blocked adrenocorticotropic hormone stimulation in response to corticotropin-releasing hormone in normal-weight men 126 . Although oxytocin reduces cortisol levels, hypoadrenalism is not a reported adverse effect of this drug at therapeutic doses. Further research is needed to determine whether the effects of oxytocin on the HPA axis lead to an improved metabolic profile.
Therapeutic potential
Oxytocin and interventions targeting related pathways to increase the actions of the oxytocin signal are promising agents in the treatment of obesity and metabolic disorders, including diabetes mellitus (FIG. 2) . However, some important points must be considered in the development of oxytocin therapeutics, including the short half-life 31 of oxytocin and the current limitations of our knowledge regarding the mechanisms and actions of oxytocin, as well as the safety of chronic administration in humans.
Synthetic oxytocin is approved by the FDA and widely used for induction of labour and control of postpartum uterine bleeding, and it is readily available in intravenous and intramuscular formulations 127 . Given the short half-life of oxytocin (on the order of 2-8 min in peripheral blood 128, 129 and 19-28 min in CSF 130, 131 ), intramuscular or intravenous bolus administration are not feasible for chronic administration. Although not currently approved by the FDA, intranasal formulations of oxytocin are commercially available outside the USA (for instance, in Europe) to facilitate milk letdown in nursing mothers and have been used in human investigations 132 . However, the intranasal formulation is inconvenient (it consists of 24 IU or six sprays of 4 IU of oxytocin given four times per day) and results in imprecise dosing. Oxytocin is a pulsatile hormone [133] [134] [135] [136] , and the implications of basal (or continuous) versus pulsatile (or bolus) oxytocin exposure are not yet clear. Furthermore, the effect of oxytocin feedforward regulation (that is, stimulation of oxytocin release by oxytocin) in extending effects of exogenously administered oxytocin is not well defined. In diet-induced obese mice, continuous subcutaneous administration of oxytocin with a minipump is more than three times more effective in achieving weight reduction than a single daily injection of the same dose (13.0% versus 3.6%) 37 , indicating that longer-acting oxytocin formulations might have greater efficacy than current options. Longer-acting oxytocin analogues, such as carbetocin, [Ser4,Ile8]-oxytocin and [Asu1,6]-oxytocin, have been developed, and they improve metabolic parameters (such as weight loss and glucose homeostasis) in obese diabetic mice 26, 36 . Improving our currently limited mechanistic understanding of how oxytocin works in humans will be a critical step in bringing oxytocin therapeutics into the clinic. Elucidating the full range of on-target and off-target effects to optimize efficacy and minimize tolerability and safety concerns will also be important. Many unanswered questions exist regarding how oxytocin results in metabolic effects, and the specific role of central versus peripheral pathways. Optimal dosing Nature Reviews | Endocrinology Oxytocin reduces body weight and fat and improves glucose homeostasis, highlighting its potential as a targeted therapy for metabolic disorders such as obesity and diabetes mellitus.
will also need to be established. Pharmacokinetic studies are limited by challenges in accurately measuring oxytocin levels 39 . Newer LC-MS methods might be useful in overcoming these limitations.
Although oxytocin is often administered to women around the time of childbirth, chronic use of oxytocin is not well studied, and its safety for metabolic indications has not yet been established. A direct comparison of doses is difficult because oxytocin is given intravenously as a continuous infusion to induce labour, whereas single doses of intranasal oxytocin (four times per day) are under investigation for weight loss. However, the dose of intranasal oxytocin that reduces food intake, increases the use of fat as a fuel for the body and improves glucose homeostasis in men (24 IU) 51, 52, 76, 117 falls within the range of total intranasal oxytocin that was used in a series of patients receiving oxytocin for the induction and maintenance of labour in 1968-1970, when intranasal oxytocin was used clinically as an alternative to intravenous oxytocin 137 . In one series, the mean total dose of oxytocin used for induction or stimulation of labour was 99 IU 138 , which is similar to the total daily dose that is under study for obesity (96 IU) 36, 99 . Based primarily on our current knowledge of possible adverse effects of oxytocin in labour and delivery, key safety issues that will need to be assessed with chronic use for metabolic disease include the risk of cardiovascular events such as arrhythmias and changes in blood pressure as well as hyponatraemia 127 . Less concerning adverse effects that could limit tolerability include headache and nausea 127 . Oxytocin for metabolic indications would be contraindicated in pregnancy given the risk of uterine contractions. Investigations of chronic intranasal administration of oxytocin in humans have extended up to 6 months with no serious safety concerns reported 36, 75, 107, 132, [139] [140] [141] [142] .
Although oxytocin is under investigation as a potential therapy for neuropsychiatric disorders, such as autism spectrum disorders, in children 141 , the long-term consequences of oxytocin administration during development are unknown and warrant investigation. Further study of chronic oxytocin use will be important, particularly in patients with obesity and its associated comorbidities, to demonstrate safety in this population.
Alternative ways to increase oxytocin signalling, for instance, by promoting oxytocin secretion, increasing oxytocin receptor activity or inhibiting oxytocin degradation, should also be explored.
Conclusions
Translational human studies are beginning to define the effects of oxytocin on eating behaviour and metabolism and support the therapeutic potential of oxytocin-based drugs for metabolic disorders, such as obesity and diabetes mellitus. Optimizing measurement techniques for biological samples is a critical step in improving our understanding of oxytocin physiology and translational applications. Further research examining dose-dependent effects and underlying mechanisms of oxytocin using different routes of administration (for example, intranasal versus intravenous and bolus versus continuous oxytocin exposure) and taking sex and physiologic context into account will be important. The safety and tolerability of chronic oxytocin use in relevant clinical populations must also be established. Alternative ways to increase oxytocin signalling (for example, pharmacologic agents that increase secretion, act at the oxytocin receptor or inhibit oxytocin breakdown) should also be considered. Improving our mechanistic understanding of how and where oxytocin acts in humans will be critical to advancing clinical therapies. 
